Congenital Chylothorax Open Access to Scientific and Medical Research DOI
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Chylothorax After Left Side Pneumothorax Surgery Managed by OK-432 Pleurodesis: an Effective Alternative
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Available online at www.sciencedirect.com ScienceDirect Journal of the Chinese Medical Association 77 (2014) 653e655 www.jcma-online.com Case Report Chylothorax after left side pneumothorax surgery managed by OK-432 pleurodesis: An effective alternative Sheng-Yang Huang a, Chou-Ming Yeh b, Chia-Man Chou a,c,*, Hou-Chuan Chen a a Division of Pediatric Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, ROC b Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan, ROC c National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC Received June 13, 2013; accepted September 23, 2013 Abstract Chylothorax, a relatively rare complication of thoracic surgery, mostly occurs on the right side. We present a 16-year-old male who received thoracoscopic surgery for left spontaneous pneumothorax. Chylothorax developed on the postoperative 2nd day and resolved after diet control on the 4th day. Unfortunately, chylothorax recurred 2 weeks later. Chest drainage and nil per os with total parental nutrition were given but in vain. Thereafter, chemical pleurodesis with OK-432 was performed. Chylothorax resolved on the next day. The relevant literature is reviewed and possible pathogenesis clarified. Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved. Keywords: chylothorax; pleurodesis; pneumothorax 1. Introduction 2. Case Report Postoperative chylothorax is infrequent but potentially A 16-year-old male patient had the history of left chest pain life-threatening and time-consuming to manage. Associated for 5 days. -
Section 8 Pulmonary Medicine
SECTION 8 PULMONARY MEDICINE 336425_ST08_286-311.indd6425_ST08_286-311.indd 228686 111/7/121/7/12 111:411:41 AAMM CHAPTER 66 EVALUATION OF CHRONIC COUGH 1. EPIDEMIOLOGY • Nearly all adult cases of chronic cough in nonsmokers who are not taking an ACEI can be attributed to the “Pathologic Triad of Chronic Cough” (asthma, GERD, upper airway cough syndrome [UACS; previously known as postnasal drip syndrome]). • ACEI cough is idiosyncratic, occurrence is higher in female than males 2. PATHOPHYSIOLOGY • Afferent (sensory) limb: chemical or mechanical stimulation of receptors on pharynx, larynx, airways, external auditory meatus, esophagus stimulates vagus and superior laryngeal nerves • Receptors upregulated in chronic cough • CNS: cough center in nucleus tractus solitarius • Efferent (motor) limb: expiratory and bronchial muscle contraction against adducted vocal cords increases positive intrathoracic pressure 3. DEFINITION • Subacute cough lasts between 3 and 8 weeks • Chronic cough duration is at least 8 weeks 4. DIFFERENTIAL DIAGNOSIS • Respiratory tract infection (viral or bacterial) • Asthma • Upper airway cough syndrome (postnasal drip syndrome) • CHF • Pertussis • COPD • GERD • Bronchiectasis • Eosinophilic bronchitis • Pulmonary tuberculosis • Interstitial lung disease • Bronchogenic carcinoma • Medication-induced cough 5. EVALUATION AND TREATMENT OF THE COMMON CAUSES OF CHRONIC COUGH • Upper airway cough syndrome: rhinitis, sinusitis, or postnasal drip syndrome • Presentation: symptoms of rhinitis, frequent throat clearing, itchy -
Chylothorax As Rare Manifestation of Pleural Involvement in Waldenström Macroglobulinemia: Mechanisms and Management
210 Lymphology 49 (2016) 210-217 CHYLOTHORAX AS RARE MANIFESTATION OF PLEURAL INVOLVEMENT IN WALDENSTRÖM MACROGLOBULINEMIA: MECHANISMS AND MANAGEMENT G. Leoncini, C.C. Campisi, G. Fraternali Orcioni, F. Patrone, F. Ferrando, C. Campisi Unit of Thoracic Surgery (GL), Unit of General & Lymphatic Surgery - Microsurgery and Department of Surgical Sciences and Integrated Diagnostics (DISC) (CCC,CC), Unit of Pathology (GFO), Unit of Internal Medicine and Medical Oncology and Department of Internal Medicine (DIMI) (FP,FF), IRCCS San Martino University Hospital - National Institute for Cancer Research, and University School of Medicine and Pharmaceutics, Genoa, Italy ABSTRACT increase of IgM level. Pleuropulmonary involvement is reported to be rare (from 0 Here we report the clinical, pathological, to 5% of cases), and it usually occurs during and immunological features of a rare case of the late phase of the disease (3,4). In such a Waldenström macroglobulinemia (WM) with scenario, chylothorax is rarely observed in pleural infiltrations. An atypical chylothorax, WM patients; indeed only seven cases have successfully treated by videothoracoscopy, been reported in the literature (5-11). We represented the main clinical feature of this report the case of a 66-year old man with the case of low-grade lymphoplasmacytic main clinical presentation of pleural lymphoma. Pleuropulmonary manifestations infiltrations with right chylothorax following are rare (from 0 to 5% of cases) in WM, with immunochemotherapy. An extra-bone chylothorax observed in just seven patients marrow involvement was suggested by both worldwide. In addition to describing this pleural fluid examination and multiple uncommon clinical presentation, we investi- pleural biopsies in parallel with a marked gate hypothetical pathogenetic mechanisms decrease of bone marrow (BM) participation causing chylothorax and through an up-to- (tumor cells in BM from 70% to 8%). -
Right Heart Pressures in Bronchial Asthma
Thorax: first published as 10.1136/thx.26.1.39 on 1 January 1971. Downloaded from Thorax (1971), 26, 39. Right heart pressures in bronchial asthma R. F. GUNSTONE St. George's Hospital, London S.W.1 Right heart pressures, electrocardiograms, blood gases, and peak expiratory flow rates were measured in nine patients admitted to hospital with severe bronchial asthma. Low or normal right heart pressures were found despite electrocardiographic changes in five patients consisting of right atrial P waves, abnormal right axis deviation, and in one patient T-wave changes in pre- cordial leads. These electrocardiographic changes reverted towards normal on recovery of the patient from the asthmatic attack. Electrocardiographic changes suggestive of right The procedure was carried out in the general ward heart embarrassment have been noted in acute with the patient in the sitting position supported at 60 bronchial asthma, particularly right atrial P waves to 90 degrees to the horizontal because orthopnoea (P and abnormal right axis deviation was always present. Immediately after catheterization pulmonale) the peak expiratory flow rate was measured with a (Harkavy and Romanoff, 1942; Miyamato, Wright peak flow meter (Wright and McKerrow, Bastaroli, and Hoffman, 1961; Ambiavagar, 1959) and blood (capillary or arterial) was taken for Jones and Roberts, 1967). These observations measurement of pH, Pco2, and standard bicarbonate raise the possibility that death in bronchial asthma by the Astrup method (Astrup, J0rgensen, Andersen, may be due to acute cor pulmonale although and Engel, 1960). The peak flow rate and electro- copyright. necropsy evidence is against this suggestion (Earle, cardiogram were repeated after recovery. -
Severe Asthma Is Associated with a Remodeling of the Pulmonary Arteries in Horses
bioRxiv preprint doi: https://doi.org/10.1101/2020.04.15.042903; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Severe asthma is associated with a remodeling of the pulmonary arteries in horses Remodeling of pulmonary arteries in severe equine asthma Serena Ceriotti1,2, Michela Bullone1, Mathilde Leclere1, Francesco Ferrucci2, Jean-Pierre Lavoie1* 1 Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint- Hyacinthe, Quebec, Canada 2 Department of Health, Animal Science and Food Safety, Università degli Studi di Milano, Milano, Italy Dr. Ceriotti current address is Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA Dr. Bullone current address is Department of Veterinary Science, Università degli Studi di Torino, Grugliasco, Italy *Corresponding author: [email protected] Serena Ceriotti and Jean-Pierre Lavoie conceived and designed the work. Serena Ceriotti, Michela Bullone and Mathilde Leclere acquired clinical data, collected, processed and prepared histological and immunostained samples. Serena Ceriotti performed histomorphometric studies and statistical analysis. Serena Ceriotti, Jean-Pierre Lavoie and Francesco Ferrucci prepared and edited the manuscript prior to submission. Michela Bullone and Mathilde Leclere edited the manuscript prior to submission. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.04.15.042903; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. -
Allergic Bronchopulmonary Aspergillosis: Diagnostic and Treatment Challenges
y & Re ar sp Leonardi et al., J Pulm Respir Med 2016, 6:4 on ir m a l to u r P y DOI: 10.4172/2161-105X.1000361 f M o e Journal of l d a i n c r i n u e o J ISSN: 2161-105X Pulmonary & Respiratory Medicine Review Article Open Access Allergic Bronchopulmonary Aspergillosis: Diagnostic and Treatment Challenges Lucia Leonardi*, Bianca Laura Cinicola, Rossella Laitano and Marzia Duse Department of Pediatrics and Child Neuropsychiatry, Division of Allergy and Clinical Immunology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy Abstract Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder, occurring mostly in asthmatic and cystic fibrosis patients, caused by an abnormal T-helper 2 lymphocyte response of the host to Aspergillus fumigatus antigens. ABPA diagnosis is defined by clinical, laboratory and radiological criteria including active asthma, immediate skin reactivity to A. fumigatus antigens, total serum IgE levels>1000 IU/mL, fleeting pulmonary parenchymal opacities and central bronchiectases that represent an irreversible complication of ABPA. Despite advances in our understanding of the role of the allergic response in the pathophysiology of ABPA, pathogenesis of the disease is still not completely clear. In addition, the absence of consensus regarding its prevalence, diagnostic criteria and staging limits the possibility of diagnosing the disease at early stages. This may delay the administration of a therapy that can potentially prevent permanent lung damage. Long-term management is still poorly studied. Present primary therapies, based on clinical experience, are not yet standardized. These consist in oral corticosteroids, which control acute symptoms by mitigating the allergic inflammatory response, azoles and, more recently, anti-IgE antibodies. -
Pulmonary Hypertension ______
Pulmonary Hypertension _________________________________________ What is it? High blood pressure in the arteries that supply the lungs is called pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The blood pressure measured by a cuff on your arm isn’t directly related to the pressure in your lungs. The blood vessels that supply the lungs constrict and their walls thicken, so they can’t carry as much blood. As in a kinked garden hose, pressure builds up and backs up. The heart works harder, trying to force the blood through. If the pressure is high enough, eventually the heart can’t keep up, and less blood can circulate through the lungs to pick up oxygen. Patients then become tired, dizzy and short of breath. If a pre-existing disease triggered the PH, doctors call it secondary pulmonary hypertension. That’s because it’s secondary to another problem, such as a left heart or lung disorder. However, congenital heart disease can cause PH that’s similar to PH when the cause isn’t known, i.e., idiopathic or unexplained pulmonary arterial hypertension. In this case, the PAH is considered pulmonary arterial hypertension associated with congenital heart disease, such as associated with a VSD or ASD (either repaired or unrepaired). The problem is due to scarring in the small arteries in the lung. It’s important to repair congenital heart problems (when possible) before permanent pulmonary hypertensive changes develop. Intracardiac left-to-right shunts (such as a ventricular or atrial septal defect, a hole in the wall between the two ventricles or atria) can cause too much blood flow through the lungs. -
Allergic Bronchopulmonary Aspergillosis
Allergic Bronchopulmonary Aspergillosis Karen Patterson1 and Mary E. Strek1 1Department of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, Illinois Allergic bronchopulmonary aspergillosis (ABPA) is a complex clinical type of pulmonary disease that may develop in response to entity that results from an allergic immune response to Aspergillus aspergillus exposure (6) (Table 1). ABPA, one of the many fumigatus, most often occurring in a patient with asthma or cystic forms of aspergillus disease, results from a hyperreactive im- fibrosis. Sensitization to aspergillus in the allergic host leads to mune response to A. fumigatus without tissue invasion. activation of T helper 2 lymphocytes, which play a key role in ABPA occurs almost exclusively in patients with asthma or recruiting eosinophils and other inflammatory mediators. ABPA is CF who have concomitant atopy. The precise incidence of defined by a constellation of clinical, laboratory, and radiographic ABPA in patients with asthma and CF is not known but it is criteria that include active asthma, serum eosinophilia, an elevated not high. Approximately 2% of patients with asthma and 1 to total IgE level, fleeting pulmonary parenchymal opacities, bronchi- 15% of patients with CF develop ABPA (2, 4). Although the ectasis, and evidence for sensitization to Aspergillus fumigatus by incidence of ABPA has been shown to increase in some areas of skin testing. Specific diagnostic criteria exist and have evolved over the world during months when total mold counts are high, the past several decades. Staging can be helpful to distinguish active disease from remission or end-stage bronchiectasis with ABPA occurs year round, and the incidence has not been progressive destruction of lung parenchyma and loss of lung definitively shown to correlate with total ambient aspergillus function. -
Cryptogenic Organizing Pneumonia
462 Cryptogenic Organizing Pneumonia Vincent Cottin, M.D., Ph.D. 1 Jean-François Cordier, M.D. 1 1 Hospices Civils de Lyon, Louis Pradel Hospital, National Reference Address for correspondence and reprint requests Vincent Cottin, Centre for Rare Pulmonary Diseases, Competence Centre for M.D., Ph.D., Hôpital Louis Pradel, 28 avenue Doyen Lépine, F-69677 Pulmonary Hypertension, Department of Respiratory Medicine, Lyon Cedex, France (e-mail: [email protected]). University Claude Bernard Lyon I, University of Lyon, Lyon, France Semin Respir Crit Care Med 2012;33:462–475. Abstract Organizing pneumonia (OP) is a pathological pattern defined by the characteristic presence of buds of granulation tissue within the lumen of distal pulmonary airspaces consisting of fibroblasts and myofibroblasts intermixed with loose connective matrix. This pattern is the hallmark of a clinical pathological entity, namely cryptogenic organizing pneumonia (COP) when no cause or etiologic context is found. The process of intraalveolar organization results from a sequence of alveolar injury, alveolar deposition of fibrin, and colonization of fibrin with proliferating fibroblasts. A tremen- dous challenge for research is represented by the analysis of features that differentiate the reversible process of OP from that of fibroblastic foci driving irreversible fibrosis in usual interstitial pneumonia because they may determine the different outcomes of COP and idiopathic pulmonary fibrosis (IPF), respectively. Three main imaging patterns of COP have been described: (1) multiple patchy alveolar opacities (typical pattern), (2) solitary focal nodule or mass (focal pattern), and (3) diffuse infiltrative opacities, although several other uncommon patterns have been reported, especially the reversed halo sign (atoll sign). -
PULMONARY HYPERTENSION in SCLERODERMA PULMONARY HYPERTENSION Pulmonary Hypertension (PH) Is High Blood Pressure in the Blood Vessels of the Lungs
PULMONARY HYPERTENSION IN SCLERODERMA PULMONARY HYPERTENSION Pulmonary hypertension (PH) is high blood pressure in the blood vessels of the lungs. If the high blood pressure in the lungs is due to narrowing of the pulmonary arteries leading to increased pulmonary vascular resistance, it is known as pulmonary arterial hypertension (PAH). When the blood pressure inside the pulmonary vessels is high, the right side of the heart has to pump harder to move blood into the lungs to pick up oxygen. This can lead to failure of the right side of the heart. Patients with scleroderma are at increased risk for developing PH from several mechanisms. Frequently patients with scleroderma have multiple causes of their PH. Patients who have limited cutaneous scleroderma (formerly known as CREST syndrome) are more likely to have PAH than those patients who have diffuse cutaneous systemic sclerosis. PAH may be the result of the same processes that cause damage to small blood vessels in the systemic circulation of patients with scleroderma. The lining cells of the blood vessels (endothelial cells) are injured and excessive connective tissue is laid down inside the blood vessel walls. The muscle that constricts the blood vessel may overgrow and narrow the blood vessel. Other scleroderma patients may have PH because they have significant scarring (fibrosis) of their lungs. This reduces the blood oxygen level, which in turn, may cause a reflex increase in blood pressure in the pulmonary arteries. WHAT ARE THE SYMPTOMS OF PULMONARY HYPERTENSION? Patients with mild PH may have no symptoms. Patients with moderate or severe PH usually notice shortness of breath (dyspnea), especially with exercise. -
Pulmonary Arteriole Gene Expression Signature in Idiopathic Pulmonary Fibrosis
Eur Respir J 2013; 41: 1324–1330 DOI: 10.1183/09031936.0084112 CopyrightßERS 2013 Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis Nina M. Patel*,#, Steven M. Kawut", Sanja Jelic*, Selim M. Arcasoy*,#,+, David J. Lederer*,#,+ and Alain C. Borczuk1 ABSTRACT: A third of patients with idiopathic pulmonary fibrosis (IPF) develop pulmonary AFFILIATIONS hypertension (PH-IPF), which is associated with increased mortality. Whether an altered gene *Division of Pulmonary, Allergy and Critical Care Medicine, Columbia expression profile in the pulmonary vasculature precedes the clinical onset of PH-IPF is unknown. University, New York, NY, We compared gene expression in the pulmonary vasculature of IPF patients with and without PH #Interstitial Lung Disease Program, with controls. New York Presbyterian Hospital, New Pulmonary arterioles were isolated using laser capture microdissection from 16 IPF patients: York, NY, "Dept of Medicine and the Center for eight with PH (PH-IPF) and eight with no PH (NPH-IPF), and seven controls. Probe was prepared Clinical Epidemiology and from extracted RNA, and hybridised to Affymetrix Hu133 2.0 Plus genechips. Biometric Research Biostatistics, Perelman School of Branch array tools and Ingenuity Pathway Analysis software were used for analysis of the Medicine, University of Pennsylvania, microarray data. Philadelphia, PA, +Lung Transplantation Program, New Univariate analysis revealed 255 genes that distinguished IPF arterioles from controls York Presbyterian Hospital, New York, (p,0.001). Mediators of vascular smooth muscle and endothelial cell proliferation, Wnt signalling NY, and and apoptosis were differentially expressed in IPF arterioles. Unsupervised and supervised 1Dept of Pathology and Cell Biology, clustering analyses revealed similar gene expression in PH-IPF and NPH-IPF arterioles. -
Allergic Bronchopulmonary Aspergillosis
Published online: 2021-07-30 CHEST RADIOLOGY Pictorial essay: Allergic bronchopulmonary aspergillosis Ritesh Agarwal, Ajmal Khan, Mandeep Garg1, Ashutosh N Aggarwal, Dheeraj Gupta Departments of Pulmonary Medicine and 1Radiodiagnosis, Postgraduate Institute of Medical Education and Research, Sector-12, Chandigarh - 160 012, India Correspondence: Dr. Ritesh Agarwal, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Sector-12, Chandigarh - 160 012, India. E-mail: [email protected] Abstract Allergic bronchopulmonary aspergillosis (ABPA) is the best-known allergic manifestation of Aspergillus-related hypersensitivity pulmonary disorders. Most patients present with poorly controlled asthma, and the diagnosis can be made on the basis of a combination of clinical, immunological, and radiological findings. The chest radiographic findings are generally nonspecific, although the manifestations of mucoid impaction of the bronchi suggest a diagnosis of ABPA. High-resolution CT scan (HRCT) of the chest has replaced bronchography as the initial investigation of choice in ABPA. HRCT of the chest can be normal in almost one-third of the patients, and at this stage it is referred to as serologic ABPA (ABPA-S). The importance of central bronchiectasis (CB) as a specific finding in ABPA is debatable, as almost 40% of the lobes are involved by peripheral bronchiectasis. High-attenuation mucus (HAM), encountered in 20% of patients with ABPA, is pathognomonic of ABPA. ABPA should be classified based on the presence or absence of HAM as ABPA-S (mild), ABPA-CB (moderate), and ABPA-CB-HAM (severe), as this classification not only reflects immunological severity but also predicts the risk of recurrent relapses. Key words: Allergic bronchopulmonary aspergillosis; allergic bronchopulmonary aspergillosis; aspergillus; chest radiograph; computed tomography; High-resolution CT scan Introduction A.